Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.

Publication Type:

Journal Article

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 28, Issue 22, p.3605-10 (2010)

Keywords:

2010, ADENOCARCINOMA, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Center-Authored Paper, Deoxycytidine, Disease-Free Survival, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Public Health Sciences Division

Abstract:

Patients with advanced pancreas cancer present with disease that is poorly responsive to conventional therapies. Preclinical and early clinical evidence has supported targeting the epidermal growth factor receptor (EGFR) signaling pathway in patients with pancreas cancer. This trial was conducted to evaluate the contribution of an EGFR-targeted agent to standard gemcitabine therapy. Cetuximab is a monoclonal antibody against the ligand-binding domain of the receptor.